Cargando…
Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome
BACKGROUND: Berberine (BER) and mangiferin are known natural dipeptidyl peptidase (DPP-IV) inhibitors. Hence, the study was designed to elucidate the mechanism of action of natural DPP-IV inhibitors (BER and MNG) in experimentally induced diabetes with metabolic syndrome. AIM: The aim of this study...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666829/ https://www.ncbi.nlm.nih.gov/pubmed/38023603 http://dx.doi.org/10.4103/ijabmr.ijabmr_115_23 |
_version_ | 1785139125747187712 |
---|---|
author | Suman, Rajesh Kumar Borde, Manjusha K Mohanty, Ipseeta Ray Singh, Hemant Kumar |
author_facet | Suman, Rajesh Kumar Borde, Manjusha K Mohanty, Ipseeta Ray Singh, Hemant Kumar |
author_sort | Suman, Rajesh Kumar |
collection | PubMed |
description | BACKGROUND: Berberine (BER) and mangiferin are known natural dipeptidyl peptidase (DPP-IV) inhibitors. Hence, the study was designed to elucidate the mechanism of action of natural DPP-IV inhibitors (BER and MNG) in experimentally induced diabetes with metabolic syndrome. AIM: The aim of this study was to observe mechanism through which natural DPP-IV inhibitor works in diabetes with metabolic syndrome rat model. MATERIALS AND METHODS: Wistar rats were fed high-fat diet for 10 weeks and challenged with streptozotocin (STZ) (40 mg/kg) at the 3(rd) week (high-fat diabetic control [HF-DC] group). After the confirmation of metabolic syndrome in the setting of diabetes, monotherapy (metformin [MET], vildagliptin [VIL], BER, and MNG) and combination (MET + VIL, MET + BER, and MET + MNG) therapy was orally fed to these rats from the 4(th) to 10(th) weeks. RESULTS: Insulin resistance (IR) was seen in the HF-DC group as indicated by raised homeostasis model assessment of IR (HOMA-IR) in HF-DC group as compared with normal control (NC) groups. The treatment groups reduced IR as shown by a decrease in HOMA-IR as compared with HF-DC group rats. The marked reduction (P < 0.001) of beta-cell function was observed in the HF-DC group as a reduced level of HOMA for beta-cell function (HOMA-β) was found as compared with the NC group. Increases in HOMA-β as compared to the HFDC group were observed in the therapy groups. The treatment group significantly reduced cholesterol and atherogenic index. The treatment group showed significant preservation of beta-cell mass as per immunohistochemistry and significant anti-apoptotic activity as per Terminal Deoxyribonucleotidyl Transferase-Mediated dUTP Nick End Labeling assay report. The treated rats significantly (P < 0.05) reduced high-sensitivity C-reactive protein. Lipid peroxidation (thiobarbituric acid reactive substances) marker (P < 0.001) was significantly reduced in the treatment group. CONCLUSION: The natural DPP-IV inhibitors BER and MNG treatment showed beneficial effects on various components of metabolic syndrome. |
format | Online Article Text |
id | pubmed-10666829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-106668292023-07-01 Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome Suman, Rajesh Kumar Borde, Manjusha K Mohanty, Ipseeta Ray Singh, Hemant Kumar Int J Appl Basic Med Res Original Article BACKGROUND: Berberine (BER) and mangiferin are known natural dipeptidyl peptidase (DPP-IV) inhibitors. Hence, the study was designed to elucidate the mechanism of action of natural DPP-IV inhibitors (BER and MNG) in experimentally induced diabetes with metabolic syndrome. AIM: The aim of this study was to observe mechanism through which natural DPP-IV inhibitor works in diabetes with metabolic syndrome rat model. MATERIALS AND METHODS: Wistar rats were fed high-fat diet for 10 weeks and challenged with streptozotocin (STZ) (40 mg/kg) at the 3(rd) week (high-fat diabetic control [HF-DC] group). After the confirmation of metabolic syndrome in the setting of diabetes, monotherapy (metformin [MET], vildagliptin [VIL], BER, and MNG) and combination (MET + VIL, MET + BER, and MET + MNG) therapy was orally fed to these rats from the 4(th) to 10(th) weeks. RESULTS: Insulin resistance (IR) was seen in the HF-DC group as indicated by raised homeostasis model assessment of IR (HOMA-IR) in HF-DC group as compared with normal control (NC) groups. The treatment groups reduced IR as shown by a decrease in HOMA-IR as compared with HF-DC group rats. The marked reduction (P < 0.001) of beta-cell function was observed in the HF-DC group as a reduced level of HOMA for beta-cell function (HOMA-β) was found as compared with the NC group. Increases in HOMA-β as compared to the HFDC group were observed in the therapy groups. The treatment group significantly reduced cholesterol and atherogenic index. The treatment group showed significant preservation of beta-cell mass as per immunohistochemistry and significant anti-apoptotic activity as per Terminal Deoxyribonucleotidyl Transferase-Mediated dUTP Nick End Labeling assay report. The treated rats significantly (P < 0.05) reduced high-sensitivity C-reactive protein. Lipid peroxidation (thiobarbituric acid reactive substances) marker (P < 0.001) was significantly reduced in the treatment group. CONCLUSION: The natural DPP-IV inhibitors BER and MNG treatment showed beneficial effects on various components of metabolic syndrome. Wolters Kluwer - Medknow 2023 2023-09-25 /pmc/articles/PMC10666829/ /pubmed/38023603 http://dx.doi.org/10.4103/ijabmr.ijabmr_115_23 Text en Copyright: © 2023 International Journal of Applied and Basic Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Suman, Rajesh Kumar Borde, Manjusha K Mohanty, Ipseeta Ray Singh, Hemant Kumar Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome |
title | Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome |
title_full | Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome |
title_fullStr | Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome |
title_full_unstemmed | Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome |
title_short | Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome |
title_sort | mechanism of action of natural dipeptidyl peptidase-iv inhibitors (berberine and mangiferin) in experimentally induced diabetes with metabolic syndrome |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666829/ https://www.ncbi.nlm.nih.gov/pubmed/38023603 http://dx.doi.org/10.4103/ijabmr.ijabmr_115_23 |
work_keys_str_mv | AT sumanrajeshkumar mechanismofactionofnaturaldipeptidylpeptidaseivinhibitorsberberineandmangiferininexperimentallyinduceddiabeteswithmetabolicsyndrome AT bordemanjushak mechanismofactionofnaturaldipeptidylpeptidaseivinhibitorsberberineandmangiferininexperimentallyinduceddiabeteswithmetabolicsyndrome AT mohantyipseetaray mechanismofactionofnaturaldipeptidylpeptidaseivinhibitorsberberineandmangiferininexperimentallyinduceddiabeteswithmetabolicsyndrome AT singhhemantkumar mechanismofactionofnaturaldipeptidylpeptidaseivinhibitorsberberineandmangiferininexperimentallyinduceddiabeteswithmetabolicsyndrome |